WO2003020258A1 - Medicament contre la grippe de type a - Google Patents

Medicament contre la grippe de type a Download PDF

Info

Publication number
WO2003020258A1
WO2003020258A1 PCT/JP2002/008940 JP0208940W WO03020258A1 WO 2003020258 A1 WO2003020258 A1 WO 2003020258A1 JP 0208940 W JP0208940 W JP 0208940W WO 03020258 A1 WO03020258 A1 WO 03020258A1
Authority
WO
WIPO (PCT)
Prior art keywords
airway
influenza
drugs
influenza virus
secretion
Prior art date
Application number
PCT/JP2002/008940
Other languages
English (en)
French (fr)
Inventor
Hiroshi Kido
Original Assignee
Boehringer Ingelheim International Gmbh
Techno Network Shikoku Co.,Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh, Techno Network Shikoku Co.,Ltd. filed Critical Boehringer Ingelheim International Gmbh
Priority to HU0402299A priority Critical patent/HUP0402299A3/hu
Priority to BR0212232-4A priority patent/BR0212232A/pt
Priority to NZ532019A priority patent/NZ532019A/en
Priority to CA002459492A priority patent/CA2459492A1/en
Priority to EP02762982A priority patent/EP1437134A4/en
Priority to IL16053902A priority patent/IL160539A0/xx
Priority to MXPA04002066A priority patent/MXPA04002066A/es
Priority to KR10-2004-7003276A priority patent/KR20040045429A/ko
Publication of WO2003020258A1 publication Critical patent/WO2003020258A1/ja
Priority to US10/790,448 priority patent/US20040242700A1/en
Priority to HK05101866A priority patent/HK1069526A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/JP2002/008940 2001-09-04 2002-09-03 Medicament contre la grippe de type a WO2003020258A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
HU0402299A HUP0402299A3 (en) 2001-09-04 2002-09-03 Anti-influenza drugs containing ambroxol and bromhexine and process for its preparation
BR0212232-4A BR0212232A (pt) 2001-09-04 2002-09-03 Agente antiinfluenza
NZ532019A NZ532019A (en) 2001-09-04 2002-09-03 Anti-influenza drugs
CA002459492A CA2459492A1 (en) 2001-09-04 2002-09-03 Anti-influenzal agent
EP02762982A EP1437134A4 (en) 2001-09-04 2002-09-03 FLU RESOURCES
IL16053902A IL160539A0 (en) 2001-09-04 2002-09-03 Anti-influenzal agents
MXPA04002066A MXPA04002066A (es) 2001-09-04 2002-09-03 Farmacos contra influenza.
KR10-2004-7003276A KR20040045429A (ko) 2001-09-04 2002-09-03 항인플루엔자 약제
US10/790,448 US20040242700A1 (en) 2001-09-04 2004-02-27 Anti-influenzal agent
HK05101866A HK1069526A1 (en) 2001-09-04 2005-03-03 Anti-influenza drugs

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-267236 2001-09-04
JP2001267236 2001-09-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/790,448 Continuation US20040242700A1 (en) 2001-09-04 2004-02-27 Anti-influenzal agent

Publications (1)

Publication Number Publication Date
WO2003020258A1 true WO2003020258A1 (fr) 2003-03-13

Family

ID=19093396

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008940 WO2003020258A1 (fr) 2001-09-04 2002-09-03 Medicament contre la grippe de type a

Country Status (12)

Country Link
US (1) US20040242700A1 (ja)
EP (1) EP1437134A4 (ja)
KR (1) KR20040045429A (ja)
CN (1) CN1267091C (ja)
BR (1) BR0212232A (ja)
CA (1) CA2459492A1 (ja)
HK (1) HK1069526A1 (ja)
HU (1) HUP0402299A3 (ja)
IL (1) IL160539A0 (ja)
MX (1) MXPA04002066A (ja)
NZ (1) NZ532019A (ja)
WO (1) WO2003020258A1 (ja)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
ITMI20032463A1 (it) * 2003-12-16 2005-06-17 Advance Holdings Ltd Soluzione acquosa concentrata a base di ambroxolo
CA2619863A1 (en) * 2005-08-25 2007-03-01 Boehringer Ingelheim International Gmbh Use of ambroxol for the treatment of rhinovirus infections
JP4384717B2 (ja) * 2007-03-19 2009-12-16 裕三 土田 抗ウイルス剤
JP5337405B2 (ja) 2007-09-17 2013-11-06 ザ・ホスピタル・フォー・シック・チルドレン ゴーシェ病の治療方法
EP3654960A1 (en) 2017-07-16 2020-05-27 Neuere, LLC Ambroxol to improve and/or extend healthspan, lifespan and/or mental acuity
CA3087079A1 (en) 2018-01-26 2019-08-01 Neuere, Llc Use of ambroxol to improve skin barrier function
EP3996696A1 (en) 2019-07-09 2022-05-18 Genethon Treatment of glycogen storage disease (gsd)
WO2021255129A1 (en) * 2020-06-16 2021-12-23 Spedding Research Solutions, Sas Novel use of a modulator of glucosylceramide degradation for viral infections
CA3235692A1 (en) 2021-10-28 2023-05-04 Zywie, Llc Modified forms of ambroxol for therapeutic use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
JPH06287144A (ja) * 1993-02-03 1994-10-11 Takeda Chem Ind Ltd かぜ薬製剤
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3610997A1 (de) * 1986-04-02 1987-10-15 Krewel Werke Gmbh Ambroxol-nasenspray
JPH11510168A (ja) * 1995-07-28 1999-09-07 ザ、プロクター、エンド、ギャンブル、カンパニー 呼吸障害を処理するための鎮痛剤及び抗ヒスタミン剤を含有する組成物及び方法
US5648358A (en) * 1996-03-05 1997-07-15 Mitra; Sekhar Compositions and methods for treating respiratory disorders
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008551A2 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Pharmaceutical compositions and methods for treating cold symptoms
WO1994014476A1 (en) * 1992-12-21 1994-07-07 The Procter & Gamble Company Use of s(+) antipodes of analgesic agents for the manufacture of a composition to treat respiratory disorders
JPH06287144A (ja) * 1993-02-03 1994-10-11 Takeda Chem Ind Ltd かぜ薬製剤
WO1995007103A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agent and at least one of a decongestant, an expectorant, an antihistamine and an antitussive

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] NISHIKAWA M. ET AL.: "Ambroxol suppresses influenza virus multiplication in the airway by increasing antiviral factor levels", XP002961052, accession no. STN Database accession no. 2002:542180 *
DATABASE CAPLUS [online] YANG B. ET AL.: "Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels", XP002961053, accession no. STN Database accession no. 2002:444958 *
EUROPEAN RESPIRATORY JOURNAL, vol. 19, no. 5, 2002, pages 952 - 958 *
See also references of EP1437134A4 *
TOKUSHIMA IGAKKAI, vol. 58, no. 3, 2002, pages 162 - 167 *

Also Published As

Publication number Publication date
CN1267091C (zh) 2006-08-02
CA2459492A1 (en) 2003-03-13
IL160539A0 (en) 2004-07-25
US20040242700A1 (en) 2004-12-02
NZ532019A (en) 2007-04-27
HUP0402299A2 (hu) 2005-02-28
HUP0402299A3 (en) 2008-04-28
HK1069526A1 (en) 2005-05-27
KR20040045429A (ko) 2004-06-01
CN1549708A (zh) 2004-11-24
MXPA04002066A (es) 2005-02-17
EP1437134A1 (en) 2004-07-14
EP1437134A4 (en) 2009-03-11
BR0212232A (pt) 2004-10-05

Similar Documents

Publication Publication Date Title
DE60013836D1 (de) Replikationsinhibitoren des respiratorischen synzytialvirus
PT1435915E (pt) Formas de administração oral de propiverina ou de seus sais farmaceuticamente aceitáveis com libertação prolongada da substância activa
NO20016369D0 (no) Respiratorisk syncytialvirus-replikasjonsinhibitorer
WO2003020258A1 (fr) Medicament contre la grippe de type a
NO20041277L (no) Farmasoytiske preparater for behandling av astma.
ATE392863T1 (de) Streifen zur abgabe eines mundpflegewirkstoffes
NO20016370L (no) Respiratorisk syncytialvirus-replikasjonsinhibitorer
HK1088217A1 (en) Preparation of sterile aqueous suspensions comprising micronised crystalline active ingredients for inhalation
EA200401227A1 (ru) Система доставки лекарства с контролируемым высвобождением, включающая правастатин
ATE499939T1 (de) Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend
WO2004085682A3 (de) Caspase inhibitoren, insbesondere von caspase-3, zur behandlung von influenza
DE60002885D1 (de) Wässrige formulierung zur nasalen verabreichung
BRPI0411623A (pt) forma de dosagem farmacêutica ou dietética, esporopolenina, método para a formação de uma esporopolenina funcionalizada com amina primária ou um outro revestimento de exina, método para a formação de uma esporopolenina funcionalizada com poliamino ou um outro revestimento de exina de um esporo, método para a obtenção de uma esporopolenina funcionalizada com aminoácido ou um outro revestimento de exina de um esporo, esporopolenina funcionalizada ou um outro revestimento de exina de um esporo, forma de dosagem dietética ou flavorizante, método de preenchimento de revestimentos de exina de esporos, uso da forma de dosagem e método de aplicação oral de um ingrediente ativo
ATE464878T1 (de) Pharmazeutische zusammensetzung zur nasalen anwendung von fentanyl
TW200501935A (en) Use of resveratrol for preparation of a medicament useful for the treatment of influenza virus infections
WO2008020314A3 (en) Statin stabilizing dosage formulations
WO2005051350A3 (en) Water dispersible tablet
CL2004002030A1 (es) Uso de interferon y ribavirina porque sirve para preparar un medicamento para tratar infecciones virales; composicion farmaceutica que comprende interferon, ribavirina y opcionalmente antioxidante; kit y su uso para preparar un medicamento para trata
WO2007057436A3 (en) Interferon in influenza
HUP0202931A2 (hu) Egy gyógyszerészetileg hatásos összetétel és a beadására szolgáló készülék
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE60105243D1 (de) Oral anzuwendende tramadolhaltige Teilchen zur einmal täglichen Verabreichung
ATE402719T1 (de) Injiziebare pharmazeutische zusammensetzung enthaltend ethanol zur behandlung von bandscheibenvorfällen
WO2003057224A1 (fr) Inducteur d'apoptose

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 160539

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10790448

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 20028170601

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002066

Country of ref document: MX

Ref document number: 2459492

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047003276

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002328415

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 532019

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002762982

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2002762982

Country of ref document: EP